The ability to image tumours with [111In]In-DOTA-trastuzumab by SPECT/CT and treat tumours by RIT with [225Ac]Ac-DOTA-trastuzumab presents an opportunity for a theranostic strategy for imaging and treatment of HER2-positive BC. Here, ERBB2 is linked to breast cancer.